• linkedin
  • Increase Font
  • Sharebar

    Mid-urethral slings demonstrate efficacy, few adverse effects

    A recently published review expands understanding of the effectiveness and side effects of mid-urethral sling procedures for stress urinary incontinence, providing more information for women considering minimally invasive surgical treatment.

    For the study, which was published online in the Cochrane Database of Systematic Reviews (July 1, 2015), researchers considered data from a total of 81 trials (12,113 women), 55 of which (8,652 women) directly compared mid-urethral sling surgery by the transobturator route and retropubic route, according to a press release from Cochrane. The quality of evidence from most of the trials was rated moderate, mainly because of bias or imprecision.

    Read: Despite warnings, mesh use for prolapse on the rise

    Rates of subjective cure over the short term (up to 1 year) were similar for the two procedures, ranging from 62% to 98% in the transobturator group and 71% to 97% in the retropubic group, as were objective cure rates. Subjective cure rates also were similar in the few trials that reported medium-term (1 to 5 years) and long-term (more than 5 years) results.

    Overall, both transobturator and retropubic procedures cured or significantly improved symptoms in more than 80% of women at 12 months. The cure rate decreased to around 70% in the few studies that reported 5-year results.

    NEXT: Adverse event rates low for both procedures

    Want more Urology Times?

    Weight-loss surgery may reduce incontinence

    Overactive bladder: Two drugs found better than one

    PTNS for overactive bladder: Patient selection and technique


    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available